AMO sales
This article was originally published in The Tan Sheet
Executive Summary
Advanced Medical Optics announces Aug. 2 its second-quarter net sales rose 1.7% to $261.4 mil. in part due to the April 2007 acquisition of IntraLase Corp. Recently AMO recalled its MoisturePlus product, which the firm estimates reduced eye care sales by $54 mil. (see next item). The Santa Ana, Calif.-based firm says the reduced sales include $31 mil. in returns and $23 mil. in lost sales. As a result, the company reported negative multipurpose sales of $7.8 mil. The firm also incurred recall-related costs of approximately $27 mil. AMO also says it began shipments this week of a Complete brand multipurpose solution it expects will be available to U.S. and European practitioners in late August (1"The Tan Sheet" July 30, 2007, In Brief). In addition, R&D expense rose 24.8% to $20.7 mil. or approximately 7.9% of sales compared to 6.4% in the 2006 second quarter...You may also be interested in...
AMO contact solution
Advanced Medical Optics announces July 23 it will ship a multipurpose solution in early August and expects the product will be widely available by early September. The new product will focus on "comfort and disinfection efficacy incorporating the importance of proper handling and care of contact lenses," the Santa Ana, Calif.-based firm says. The company recently recalled its Complete Moisture Plus after the Centers for Disease Control and Prevention reported a potential link between the product and Acanthamoeba keratitis, a rare eye infection (1"The Tan Sheet" June 4, 2007, In Brief). Separately, the firm says it "continues to believe in the strategic and financial rationale" for acquisition of Bausch & Lomb. AMO says it "reaffirms" its $75 per share offer which is "clearly superior and would deliver more value to B&L shareholders than the current $65 per share merger agreement with Warburg Pincus"...
Biogen’s Big Day Arrives, But Aducanumab Results Don’t Answer Key Question
Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug?
Biogen’s Big Day Arrives, But Aducanumab Results Don’t Answer Key Question
Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug?
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: